Keros Therapeutics Nabs $20M Milestone from Takeda as Elritercept…

Event summary

Keros Therapeutics expects a $20M development milestone payment from Takeda following the dosing of the first patient in the Phase 3 ELRiSE MF trial for myelofibrosis.
The payment is part of a global license agreement signed in January 2025, which included a $200M upfront payment and potential milestone payments exceeding $1.1B.
Keros plans to distribute 25% of the net proceeds from this milestone to its stockholders.
Elritercept is a ligand trap targeting TGF-ß signaling disorders, currently in development for cytopenias in myelofibrosis and myelodysplastic syndromes.

The big picture

This milestone underscores the strategic importance of Keros’ TGF-ß signaling platform, particularly in blood disorders. The deal with Takeda reflects a broader trend of biotech partnerships aimed at accelerating late-stage drug development, with Keros positioning itself as a leader in targeting these signaling pathways. The $20M payment is a drop in the bucket compared to the $1.1B in potential future milestones, highlighting the high-stakes nature of elritercept’s success.

What we're watching

Execution Risk: Whether Keros can sustain the momentum of its elritercept program through Phase 3 trials and potential regulatory approvals.
Financial Strategy: How Keros allocates the milestone payment and other proceeds to support its broader pipeline, including rinvatercept for Duchenne muscular dystrophy and ALS.
Partnership Dynamics: The pace at which Takeda advances elritercept’s commercialization outside mainland China, Hong Kong, and Macau, given the potential for over $1.1B in future milestones.